ZEN-BIO, INC.

Basic Information

P.O. BOX 13888
3200 CHAPEL HILL-NELSON BLVD.
RTP, NC, 27709-3888

Company Profile

n/a

Additional Details

Field Value
DUNS: 799863261
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Selective Fyn kinase inhibitors for treatment of metabolic disease

    Amount: $1,498,715.00

    DESCRIPTION (provided by applicant): Metabolic diseases such as type 2 diabetes (T2D), obesity and their related co-morbidities have reached epidemic proportions worldwide. While progress continues to ...

    SBIR Phase II 2014 Department of Health and Human Services
  2. Development of a drug discovery platform for human islets

    Amount: $1,754,814.00

    DESCRIPTION (provided by applicant): Diabetes and diabetes-related co-morbidities are at epidemic proportions and an enormous burden to our healthcare system. Although there has been significant progr ...

    SBIR Phase II 2014 Department of Health and Human Services
  3. Identification of potent and selective GLI1 inhibitors

    Amount: $289,934.00

    DESCRIPTION (provided by applicant): Characterization of human tumor samples and cell lines in combination with inhibitor studies in animal models has established a central role for the Hh pathway in ...

    STTR Phase I 2013 Department of Health and Human Services
  4. Development of a Drug Discovery Platform for Human Islets

    Amount: $462,386.00

    DESCRIPTION (provided by applicant): Diabetes and diabetes-related co-morbidities are at epidemic proportions and an enormous burden to our healthcare system. Although there has been significant progr ...

    SBIR Phase I 2012 Department of Health and Human Services
  5. Development of a human skeletal muscle cell-based high throughput screen for musc

    Amount: $251,144.00

    DESCRIPTION (provided by applicant): Skeletal muscle wasting is a serious condition prevalent in the aging population (sarcopenia) and in a variety of specific diseases. This condition results in loss ...

    SBIR Phase I 2011 Department of Health and Human Services
  6. Selective Fyn kinase inhibitors for treatment of metabolic disease

    Amount: $350,681.00

    DESCRIPTION (provided by applicant): Metabolic diseases such as type 2 diabetes (T2D), obesity and their related co-morbidities have reached epidemic proportions worldwide. While progress continues to ...

    SBIR Phase I 2011 Department of Health and Human Services
  7. Diabetes Therapies from Adipose Derived Stem Cells

    Amount: $363,202.00

    DESCRIPTION (provided by applicant): Diabetes affects the lives of hundreds of millions of people worldwide and the incidence rate is continuing to rise. About 8% of the US population is estimated to ...

    SBIR Phase I 2010 Department of Health and Human Services
  8. Commercialization of Human Mammary Basal / Luminal Cell System for Research

    Amount: $1,285,561.00

    DESCRIPTION (provided by applicant): Breast cancer is the second most common cancer among women. Roughly 190,000 women in the U.S. will be diagnosed with breast cancer in 2009, and 40,000 will die. Th ...

    SBIR Phase II 2010 Department of Health and Human Services
  9. Alternative human cell-based models of fatty liver disease

    Amount: $227,197.00

    DESCRIPTION (provided by applicant): Obesity and Type 2 diabetes affect the lives of millions of people worldwide, add significantly to health-related expenditures, and are seemingly unmanageable heal ...

    SBIR Phase I 2010 Department of Health and Human Services
  10. Commercialization of Human Mesothelial Cells for Research

    Amount: $1,888,394.00

    DESCRIPTION (provided by applicant): Mesothelial cells have been found to be pivotal in tumor metastasis, peritoneal dialysis, and inflammatory response. These cells are specialized epithelial cells t ...

    SBIR Phase II 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government